Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627377 | 0.85 | HRH3 (0.50) | GAACA2LMNAHRH3KCNH2 | |
| SCHEMBL19002605 | 0.84 | GAA (0.63) | GAACA2LMNANLRP3KMT2A | |
| SCHEMBL1298410 | 0.83 | HRH3 (0.51) | GAACA2HRH3KCNH2NLRP3 | |
| SCHEMBL17014702 | 0.83 | ALDH1A1 (0.59) | CA2LMNAHRH3KCNH2SMN1; SMN2 | |
| SCHEMBL19332211 | 0.83 | ALDH1A1 (0.66) | GAACA2LMNAHRH3KCNH2 | |
| SCHEMBL6012074 | 0.82 | CA2 (0.60) | CA2LMNANLRP3HPGDCA1 | |
| SCHEMBL19332530 | 0.81 | CA2 (0.51) | CA2LMNANLRP3CA1CA12 | |
| SCHEMBL19627379 | 0.81 | FBP1 (0.63) | CA2NLRP3CA1CA12CA9 | |
| SCHEMBL19627378 | 0.81 | NLRP3 (0.62) | GAALARS1LMNAHRH3KCNH2 | |
| SCHEMBL18993634 | 0.81 | NLRP3 (0.55) | NLRP3KMT2APTGS1PTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773637-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | claimed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | claimed |
| WO-1999007211-A9 | CONTROLLED GERMINATION USING INDUCIBLE PHYTATE GENE | EXSEED GENETICS L L C (US) | 1999-04-29 | — | — | WO | claimed |
| US-5608143-A | NUCLEIC ACID PROMOTER FRAGMENT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-04 | — | — | US | claimed |
| US-5364780-A | Genetic engineering with DNA and promoters | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| EP-0463056-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-02 | — | — | EP | claimed |
| WO-1990011361-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-04 | — | — | WO | claimed |
| EP-0388186-A1 | External regulation of gene expression | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-19 | — | — | EP | claimed |
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| WO-2016086169-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-5608143-A | NUCLEIC ACID PROMOTER FRAGMENT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| US-5364780-A | Genetic engineering with DNA and promoters | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0463056-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-02 | — | — | EP | disclosed |
| WO-1990011361-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-04 | — | — | WO | disclosed |
| EP-0388186-A1 | External regulation of gene expression | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, NR1H4 | GAA 846/4885CA2 1683/4885LARS1 4314/4885 |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | GAA 1962/4885CA2 2871/4885LARS1 2421/4885 |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, SLC10A2 | GAA 892/4885CA2 1722/4885LARS1 4235/4885 |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | GAA 1210/4885CA2 2889/4885LARS1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.